TJ Biotech Holding ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.8% 0.7% 1.3% 4.3%  
Credit score (0-100)  0 90 93 79 47  
Credit rating  N/A A AA A BBB  
Credit limit (kDKK)  0.0 1,890.6 2,163.4 298.4 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 1,416 1,749 53.5 70.0  
EBITDA  0.0 72.3 403 -10.2 -0.0  
EBIT  0.0 72.3 403 -10.2 -0.0  
Pre-tax profit (PTP)  0.0 120.2 562.7 -215.8 -9,513.5  
Net earnings  0.0 90.2 412.7 -215.8 -9,513.5  
Pre-tax profit without non-rec. items  0.0 120 563 -216 -9,514  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 23,071 23,484 23,268 13,755  
Interest-bearing liabilities  0.0 6.6 6.6 6.6 6.6  
Balance sheet total (assets)  0.0 23,650 24,509 23,731 18,140  

Net Debt  0.0 -1,419 -1,358 -758 -4,502  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 1,416 1,749 53.5 70.0  
Gross profit growth  0.0% 0.0% 23.5% -96.9% 30.7%  
Employees  0 1 1 0 0  
Employee growth %  0.0% 0.0% 0.0% -100.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 23,650 24,509 23,731 18,140  
Balance sheet change%  0.0% 0.0% 3.6% -3.2% -23.6%  
Added value  0.0 72.3 403.3 -10.2 -0.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 1.0 2.0 -1.0 -2.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 5.1% 23.1% -19.1% -0.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.6% 2.4% 0.3% -39.9%  
ROI %  0.0% 0.6% 2.5% 0.3% -45.2%  
ROE %  0.0% 0.4% 1.8% -0.9% -51.4%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 97.6% 95.8% 98.1% 75.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% -1,962.5% -336.8% 7,405.3% 32,159,978.6%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 435.2% 342.4% 4,489.4% 17,569.7%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 3.9 2.5 3.7 14.4  
Current Ratio  0.0 3.9 2.5 3.7 14.4  
Cash and cash equivalent  0.0 1,425.6 1,364.9 764.6 4,509.0  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 799.7 301.1 534.6 283.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 72 403 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 72 403 0 0  
EBIT / employee  0 72 403 0 0  
Net earnings / employee  0 90 413 0 0